Fujifilm to Showcase Digital Radiography Innovations at AHRA

Stamford, CT, June 28, 2017 (Booth #221)FUJIFILM Medical Systems U.S.A., Inc., will present its comprehensive portfolio of digital radiography and mammography solutions designed to optimize workflow and increase the safety and satisfaction of patients at the American Healthcare Radiology Administrators (AHRA) 2017 Annual Meeting. The event, which is a premier educational event for radiology administration, will occur on July 9-12, 2017 at the Anaheim Convention Center in Anaheim, California.

“As improving patient outcomes remains a key priority for physicians and healthcare organizations, Fujifilm is committed to providing the latest in digital breast imaging and digital radiography to maximize clinical benefits while enhancing the patient experience,” said Rob Fabrizio, director of strategic marketing, digital radiography and women’s health, FUJIFILM Medical Systems U.S.A., Inc. “At AHRA, Fujifilm will showcase its latest solutions which includes high-resolution imaging with Fujifilm’s innovative dose saving technologies.”

Fujifilm will be exhibiting the following solutions at AHRA 2017 booth #221:

· FDR AQRO: The all new FDR AQRO Mini Mobile System is a complete digital radiography system that delivers high-resolution images and low patient dose in a variety of point-of-care and dedicated use settings, all within an ultra-lightweight mini mobile cart. The system combines the best of Fujifilm’s core dose saving technologies such as Irradiation Side Sampling (ISS) and noise reduction circuitry, with Virtual Grid and an all New Dynamic Visualization II image processing to produce exceptional images at gentle dose for all patient sizes and anatomy.

· ASPIRE Cristalle: Fujifilm’s latest advancement in digital mammography includes digital breast tomosynthesis (DBT) and state-of-the-art dose saving, Hexagonal Close Pattern (HCP) image capture technology. The newest solution optimizes contrast, enables low dose and fast acquisition time, all while providing noticeable patient comfort with Fujifilm’s patented Comfort Paddle.

· FDR D-EVO GL: The FDR D-EVO GL is the world's first and only, single-exposure long-length DR detector. With easy patient positioning and rapid acquisition time, it simplifies exams for the technologist while lowering dose and discomfort for the patient. With a 17x49” field of view, it can accommodate all patient sizes and help prevent retakes, and when used with Fujifilm’s Virtual Grid, dose can be reduced as much as 50 percent compared to grid exams.

For all AHRA attendees, Fujifilm will host a complimentary breakfast symposium, “Optimizing Breast Cancer Detection, Departmental Efficiencies, and the Patient Experience,” on Wednesday, July 12, 2017 from 7:15AM – 8:15AM P.T. This educational workshop hosted by FUJIFILM Medical System U.S.A.’s Gregg Cretella, director of field sales support and David Wild, director of medical informatics, will explore the newest advances in digital mammography and medical informatics to understand how these tools can maximize financial, operational and clinical outcomes. Additionally, this session will help attendees evaluate the readiness of their current IT infrastructure and make sound decisions when considering the purchase of new breast imaging technologies. Learn more here: http://www.ahra.org/AHRA/AHRA_Conferences/Upcoming_Events/Annual_Meeting/AHRA/AnnualMeeting/AnnualMeeting_Advanced_Track_Wednesday.aspx

In addition, Fujifilm is pleased to welcome Nancy M. Cappello, Ph.D., executive director and founder of Are You Dense Inc., to Fujifilm’s booth #221 on Monday, July 10, 2017 at 11:00AM – 12:00PM for a Q&A session on early detection and patient centric care. Fujifilm is also sponsoring Dr. Cappello’s Presentation “From One Size Fits NONE to Personalized Breast Screening” which will be held at AHRA on Sunday at 4:30-5:30pm. Dr. Cappello is a patient advocate that is recognized for her work to help pass legislation that mandates the reporting of dense breast tissue to the patient and has built a global grassroots density education and reporting movement. Read Dr. Cappello’s story here: https://www.areyoudense.org/stories/nancy/

To learn more information about Fujifilm’s presence at AHRA 2017, please visit: http://ahra.fujimed.com/.

About Fujifilm

FUJIFILM Medical Systems U.S.A., Inc. is a leading provider of diagnostic imaging products and medical informatics solutions to meet the needs of healthcare facilities today and well into the future. From an unrivaled selection of digital x-ray systems, to the Synapse® brand of PACS, RIS and cardiovascular products, to advanced women’s health imaging systems, Fujifilm has products that are ideal for any size imaging environment. The Endoscopy Division of FUJIFILM Medical Systems U.S.A., Inc. supplies high quality, technologically advanced FUJINON brand endoscopes to the medical market. TeraMedica Division delivers healthcare informatics, and is the leading provider of vendor neutral, enterprise-wide solutions for unrestricted medical image management. FUJIFILM Medical Systems U.S.A., Inc. is headquartered in Stamford, CT. For more information please visit www.fujimed.com and www.fujifilmendoscopy.com.

FUJIFILM Holdings Corporation, Tokyo, Japan brings continuous innovation and leading-edge products to a broad spectrum of industries, including: healthcare, with medical systems, pharmaceuticals and cosmetics; graphic systems; highly functional materials, such as flat panel display materials; optical devices, such as broadcast and cinema lenses; digital imaging; and document products. These are based on a vast portfolio of chemical, mechanical, optical, electronic, software and production technologies. In the year ended March 31, 2016, the company had global revenues of $22.1 billion, at an exchange rate of 112.54 yen to the dollar. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com.

Around the web

GE HealthCare's flurpiridaz, the PET radiotracer that recently received FDA approval, offers several key benefits over SPECT. Jamshid Maddahi, MD, discussed the details in an exclusive interview. 

Ultrafast MCE could go on to become a go-to treatment option for obstructive coronary artery disease, according to the authors of a new first-in-human clinical study.

Elucid's PlaqueIQ was trained to turn CCTA images into interactive 3D reports that help physicians visualize the presence of atherosclerosis.

Trimed Popup
Trimed Popup